Company news
Scibase Holding Ab (OMXSTO:SCIB) news
Every Scibase Holding Ab press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
SciBase publishes information document regarding the rights issue
September 14, 2026
SciBase receives additional order from Castle Biosciences, advancing the collaboration
September 8, 2026
SCIBASE RESOLVES ON A RIGHTS ISSUE OF SHARES OF APPROXIMATELY SEK 58 MILLION
September 3, 2026
First Patient Enrolled in New Study Assessing early prediction of flares in Atopic Dermatitis by Castle Biosciences in Collaboration with...
June 10, 2026
Study that highlights Nevisense potential for prediction of AD published in leading journal
June 9, 2026
SciBase announces that the board of directors has resolved on the record date for the reverse share split
May 28, 2026
Nevisense detects skin barrier damage by chemicals used in household cleaning products in a new ex-vivo study
May 28, 2026
SciBase Announces New Research Highlighting Nevisense's Potential in Detecting Age-Related Skin Barrier Changes
May 18, 2026
SciBase publishes the Annual report for 2025
April 27, 2026
Notice to attend the annual general meeting in Scibase Holding AB (publ)
April 14, 2026
SciBase reaches milestone with over 400,000 tests sold with Nevisense
April 7, 2026
New Study Positions Nevisense's EIS as a valuable and sensitive tool for assessing skin barrier impairment
March 10, 2026
New Publication: US clinicians' real-world Nevisense experience improves melanoma detection
March 5, 2026
SciBase receives approval by FDA for extended labelling in the US
March 2, 2026
SciBase's Nevisense (EIS) Included in the US NCCN Guidelines for Melanoma which supports the use of EIS in the detection of melanoma
February 19, 2026
A new study demonstrates that Nevisense can predict atopic dermatitis in Newborns
February 17, 2026
SciBase: Recalculation of warrants of series TO 2 following rights issue and updated last day of trading in BTA from the rights issue
February 6, 2026
SciBase announces final outcome of the rights issue and the resolution on a set-off issue within the framework of the offer to repurchase...
January 27, 2026
Change of date for publication of the year-end report for the financial year 2025
January 26, 2026
Increased commitment in SciBase rights issue
January 22, 2026
SciBase publishes information document regarding rights issue
January 9, 2026
SciBase announces outcome of the offer to repurchase outstanding warrants of series TO 2
January 9, 2026
The Board of Directors of SciBase resolves on a previously communicated rights issue of shares of approximately SEK 83 million
December 29, 2025
SciBase Expands Its Intellectual Property Portfolio to include the analysis of the epithelial skin barrier with New European Patent
December 11, 2025
SciBase publishes information document regarding the offer to repurchase outstanding warrants of series TO 2
December 5, 2025
Bulletin from the extraordinary general meeting in SciBase Holding AB (publ)
December 5, 2025
Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of Directors
December 3, 2025
The Board of Directors in SciBase resolves on an offer to repurchase outstanding warrants of series TO 2 and intends to resolve on a righ...
November 7, 2025
SciBase and Castle Biosciences expand collaboration and license agreement and enter into loan agreement of SEK 20 million
November 7, 2025
Nomination Committee appointed for SciBase Holding's Annual General Meeting in 2026
October 22, 2025
Nevisense Used in Fundamental Skin Barrier Research on Atopic Dermatitis
September 26, 2025
SciBase receives initial order for clinical study from Castle Biosciences
September 23, 2025
Main owners strengthen their position in SciBase
September 10, 2025
New Clinical Publication in Karger Dermatology Confirms Reader Studies as Key to Validating Nevisense
August 28, 2025
SciBase announces outcome in directed share issue
August 1, 2025
SciBase Launches Nevisense Pilot at Leading University in Southeast Florida
July 9, 2025
SciBase: A new important customer in the US, Palm Beach Dermatology Group, has placed an initial order for 6 Nevisense.
July 7, 2025
SciBase resolves on a directed share issue of approximately SEK 11 million
June 23, 2025
SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and inten...
June 17, 2025
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
June 16, 2025
SciBase Initiates Self-Pay Model in the US to Make Nevisense Test More Accessible to Patients
June 9, 2025
SciBase Expands Further Through European Market with First Sales Order to customer in Italy
June 4, 2025
SciBase reaches milestone with over 300,000 patients tested with Nevisense
May 27, 2025